Open Payments

RAJA SIVAMANI

Type
Physician · Allopathic & Osteopathic Physicians / Dermatology
Where
ROCKLIN, CA
NPI
1811197478
Received
$2,075,267 in 1,776 records, 2019 to 2025 ($1,880,749 general, $194,518 research)
As principal investigator
$9,969,180 of research payments to others in 763 records
Source
CMS Open Payments search ↗

By year

Program yearKindRecordsAmount
2025General payment561$663,153
2025Research payment2$57,501
2024General payment520$584,800
2024Research payment11$129,213
2023General payment398$432,306
2023Research payment1$324
2022General payment165$137,702
2021General payment51$17,246
2020General payment12$44,256
2020Research payment2$2,948
2019General payment30$1,283
2019Research payment23$4,530

By company

CompanyRecordsAmountYears
Lilly USA, LLC228$292,5362019–2025
Incyte Corporation207$260,9912021–2025
E.R. Squibb & Sons, L.L.C.172$237,5942021–2025
UCB, Inc.295$230,8362021–2025
Nielsen BioSciences, Inc.3$171,6142024–2025
PFIZER INC.108$155,9642023–2025
Regeneron Healthcare Solutions, Inc.127$155,5642019–2025
ABBVIE INC.182$155,5192019–2025
Galderma Laboratories, L.P.78$106,6862021–2025
GENZYME CORPORATION61$105,0152021–2025
Eli Lilly and Company33$48,1042019–2025
LEO Pharma Inc.46$46,6782019–2025
Almirall LLC19$35,9742024–2025
Novartis Pharmaceuticals Corporation80$20,7712019–2025
SUN PHARMACEUTICAL INDUSTRIES INC.20$14,2552019–2025
Regeneron Pharmaceuticals, Inc.33$11,5902019–2024
The Daavlin Distributing Co1$10,0002025
Janssen Biotech, Inc.10$6,0342019–2025
Arcutis Biotherapeutics, Inc.9$4,0252023–2025
SANOFI US SERVICES INC.1$2,3352025
Insmed, Inc.7$1,1142025
Dermavant Sciences, Inc.19$7902023–2024
Amgen Inc.15$5492019–2025
Ortho Dermatologics, a division of Bausch Health US, LLC2$1672021–2022
Janssen Scientific Affairs, LLC3$1542019–2024
Organon Llc8$1422024–2025
Verrica Pharmaceuticals Inc.1$1112024
Celgene Corporation2$342019–2022
Janssen Research & Development, LLC1$262022
Cipher Pharmaceuticals US LLC1$182025
DUSA Pharmaceuticals, Inc.1$172019
MERZ NORTH AMERICA, INC.1$172019
Botanix SB Inc1$152025
GlaxoSmithKline, LLC.1$132019

By nature of payment

NatureRecordsAmount
Compensation for services other than consulting, including serving as faculty or as a speaker at a v374$1,393,802
Consulting Fee72$249,701
Travel and Lodging547$198,995
Research payment39$194,518
Food and Beverage733$34,915
Honoraria4$3,105
Education7$228

Records

DateCompanyAmountNatureFormProductStudyYear
2025-12-23Incyte Corporation$7,335Consulting FeeCash or cash equivalentOpzelura Drug, Dermatology2025
2025-12-23Incyte Corporation$4,890Consulting FeeCash or cash equivalentOpzelura Drug, Dermatology2025
2025-12-23LEO Pharma Inc.$4,073Compensation for services other than consulting, including serving as faculty or as a speaker at a vCash or cash equivalentANZUPGO Drug, DERMATOLOGY2025
2025-12-23Incyte Corporation$3,000Compensation for services other than consulting, including serving as faculty or as a speaker at a vCash or cash equivalentOpzelura Drug, Dermatology2025
2025-12-22ABBVIE INC.$1,725Compensation for services other than consulting, including serving as faculty or as a speaker at a vCash or cash equivalentRINVOQ Biological, IMMUNOLOGY2025
2025-12-22ABBVIE INC.$20Food and BeverageIn-kind items and servicesRINVOQ Biological, IMMUNOLOGY2025
2025-12-19Eli Lilly and Company$35Food and BeverageCash or cash equivalentTALTZ Drug, Immunology2025
2025-12-19Eli Lilly and Company$33Food and BeverageCash or cash equivalentTALTZ Drug, Immunology2025
2025-12-19Eli Lilly and Company$25Food and BeverageCash or cash equivalentTALTZ Drug, Immunology2025
2025-12-19Eli Lilly and Company$24Travel and LodgingCash or cash equivalentTALTZ Drug, Immunology2025
2025-12-18Galderma Laboratories, L.P.$12,600Consulting FeeCash or cash equivalentNEMLUVIO Drug, DERMATITIS2025
2025-12-18UCB, Inc.$7,000Compensation for services other than consulting, including serving as faculty or as a speaker at a vCash or cash equivalent2025
2025-12-18LEO Pharma Inc.$78Food and BeverageIn-kind items and servicesANZUPGO Drug, DERMATOLOGY2025
2025-12-18UCB, Inc.$60Travel and LodgingCash or cash equivalent2025
2025-12-18UCB, Inc.$38Travel and LodgingCash or cash equivalent2025
2025-12-18UCB, Inc.$8Travel and LodgingCash or cash equivalent2025
2025-12-18UCB, Inc.$8Travel and LodgingCash or cash equivalent2025
2025-12-18UCB, Inc.$6Food and BeverageCash or cash equivalent2025
2025-12-18UCB, Inc.$5Food and BeverageCash or cash equivalent2025
2025-12-17Galderma Laboratories, L.P.$5,400Compensation for services other than consulting, including serving as faculty or as a speaker at a vCash or cash equivalentNEMLUVIO Drug, DERMATITIS2025
2025-12-17Galderma Laboratories, L.P.$5,400Compensation for services other than consulting, including serving as faculty or as a speaker at a vCash or cash equivalentNEMLUVIO Drug, DERMATITIS2025
2025-12-17Nielsen BioSciences, Inc.$3,625Consulting FeeCash or cash equivalentCandin Biological, Immunotherapy2025
2025-12-16ABBVIE INC.$9,100Consulting FeeCash or cash equivalentRINVOQ Biological, IMMUNOLOGY2025
2025-12-16UCB, Inc.$2,075Compensation for services other than consulting, including serving as faculty or as a speaker at a vCash or cash equivalent2025
2025-12-16Incyte Corporation$121Food and BeverageCash or cash equivalentOpzelura Drug, Dermatology2025
2025-12-16Incyte Corporation$12Travel and LodgingCash or cash equivalentOpzelura Drug, Dermatology2025
2025-12-12Galderma Laboratories, L.P.$395Travel and LodgingIn-kind items and servicesNEMLUVIO Drug, DERMATITIS2025
2025-12-12Galderma Laboratories, L.P.$248Travel and LodgingIn-kind items and servicesNEMLUVIO Drug, DERMATITIS2025
2025-12-12Galderma Laboratories, L.P.$27Food and BeverageIn-kind items and servicesNEMLUVIO Drug, DERMATITIS2025
2025-12-12Galderma Laboratories, L.P.$26Food and BeverageIn-kind items and servicesNEMLUVIO Drug, DERMATITIS2025
2025-12-12Galderma Laboratories, L.P.$20Food and BeverageIn-kind items and servicesNEMLUVIO Drug, DERMATITIS2025
2025-12-11Incyte Corporation$6,000Compensation for services other than consulting, including serving as faculty or as a speaker at a vCash or cash equivalentOpzelura Drug, Dermatology2025
2025-12-11Incyte Corporation$3,000Compensation for services other than consulting, including serving as faculty or as a speaker at a vCash or cash equivalentOpzelura Drug, Dermatology2025
2025-12-11Incyte Corporation$2,250Compensation for services other than consulting, including serving as faculty or as a speaker at a vCash or cash equivalentOpzelura Drug, Dermatology2025
2025-12-10Galderma Laboratories, L.P.$840Travel and LodgingIn-kind items and servicesNEMLUVIO Drug, DERMATITIS2025
2025-12-10Galderma Laboratories, L.P.$141Food and BeverageIn-kind items and servicesNEMLUVIO Drug, DERMATITIS2025
2025-12-10Galderma Laboratories, L.P.$30Travel and LodgingIn-kind items and servicesNEMLUVIO Drug, DERMATITIS2025
2025-12-09Regeneron Healthcare Solutions, Inc.$7,259Compensation for services other than consulting, including serving as faculty or as a speaker at a vCash or cash equivalentDUPIXENT Biological, IMMUNOLOGY AND INFLAMMATION2025
2025-12-09Regeneron Healthcare Solutions, Inc.$7,259Compensation for services other than consulting, including serving as faculty or as a speaker at a vCash or cash equivalentDUPIXENT Biological, IMMUNOLOGY AND INFLAMMATION2025
2025-12-09Galderma Laboratories, L.P.$795Travel and LodgingIn-kind items and servicesNEMLUVIO Drug, DERMATITIS2025
2025-12-09Galderma Laboratories, L.P.$30Travel and LodgingIn-kind items and servicesNEMLUVIO Drug, DERMATITIS2025
2025-12-09Novartis Pharmaceuticals Corporation$12Food and BeverageIn-kind items and servicesCOSENTYX Drug, Dermatology2025
2025-12-04The Daavlin Distributing Co$10,000Consulting FeeCash or cash equivalentPhothera Phototherapy Devices Device, Phototherapy2025
2025-12-04UCB, Inc.$5,500Compensation for services other than consulting, including serving as faculty or as a speaker at a vCash or cash equivalent2025
2025-12-04LEO Pharma Inc.$2,263Compensation for services other than consulting, including serving as faculty or as a speaker at a vCash or cash equivalentADBRY Biological, DERMATOLOGY2025
2025-12-04Regeneron Healthcare Solutions, Inc.$878Travel and LodgingIn-kind items and servicesDUPIXENT Biological, IMMUNOLOGY AND INFLAMMATION2025
2025-12-04Incyte Corporation$83Travel and LodgingCash or cash equivalentOpzelura Drug, Dermatology2025
2025-12-04Incyte Corporation$70Travel and LodgingCash or cash equivalentOpzelura Drug, Dermatology2025
2025-12-04Incyte Corporation$20Food and BeverageCash or cash equivalentOpzelura Drug, Dermatology2025
2025-12-04Incyte Corporation$19Food and BeverageCash or cash equivalentOpzelura Drug, Dermatology2025
2025-12-03Incyte Corporation$543Travel and LodgingCash or cash equivalentOpzelura Drug, Dermatology2025
2025-12-03Incyte Corporation$438Travel and LodgingCash or cash equivalentOpzelura Drug, Dermatology2025
2025-12-03Regeneron Healthcare Solutions, Inc.$127Food and BeverageIn-kind items and servicesDUPIXENT Biological, IMMUNOLOGY AND INFLAMMATION2025
2025-12-03Incyte Corporation$55Travel and LodgingCash or cash equivalentOpzelura Drug, Dermatology2025
2025-12-03Incyte Corporation$17Food and BeverageCash or cash equivalentOpzelura Drug, Dermatology2025
2025-12-01Amgen Inc.$19Food and BeverageIn-kind items and servicesOTEZLA Drug, Inflammation2025
2025-11-26Novartis Pharmaceuticals Corporation$13Food and BeverageIn-kind items and servicesCOSENTYX Drug, Dermatology2025
2025-11-24E.R. Squibb & Sons, L.L.C.$1,085Consulting FeeCash or cash equivalent2025
2025-11-22Janssen Biotech, Inc.$3,825Compensation for services other than consulting, including serving as faculty or as a speaker at a vCash or cash equivalentTREMFYA Drug, Immunology2025
2025-11-20LEO Pharma Inc.$2,262Consulting FeeCash or cash equivalentADBRY Biological, DERMATOLOGY2025
2025-11-20UCB, Inc.$758Travel and LodgingIn-kind items and services2025
2025-11-20UCB, Inc.$576Travel and LodgingIn-kind items and services2025
2025-11-20UCB, Inc.$77Food and BeverageCash or cash equivalent2025
2025-11-20UCB, Inc.$71Food and BeverageCash or cash equivalent2025
2025-11-20UCB, Inc.$27Food and BeverageIn-kind items and services2025
2025-11-20UCB, Inc.$21Travel and LodgingCash or cash equivalent2025
2025-11-20UCB, Inc.$19Travel and LodgingCash or cash equivalent2025
2025-11-20UCB, Inc.$19Travel and LodgingCash or cash equivalent2025
2025-11-20E.R. Squibb & Sons, L.L.C.$18Food and BeverageCash or cash equivalentSotyktu Drug, Immunology2025
2025-11-20UCB, Inc.$16Travel and LodgingCash or cash equivalent2025
2025-11-20UCB, Inc.$16Travel and LodgingCash or cash equivalent2025
2025-11-20UCB, Inc.$14Travel and LodgingCash or cash equivalent2025
2025-11-20UCB, Inc.$14Travel and LodgingCash or cash equivalent2025
2025-11-20UCB, Inc.$14Travel and LodgingCash or cash equivalent2025
2025-11-20UCB, Inc.$11Food and BeverageCash or cash equivalent2025
2025-11-20UCB, Inc.$7Food and BeverageCash or cash equivalent2025
2025-11-20UCB, Inc.$2Food and BeverageCash or cash equivalent2025
2025-11-19Janssen Biotech, Inc.$146Food and BeverageIn-kind items and servicesTREMFYA Drug, Immunology2025
2025-11-18Novartis Pharmaceuticals Corporation$15Food and BeverageIn-kind items and servicesCOSENTYX Drug, Dermatology2025
2025-11-13UCB, Inc.$7,000Compensation for services other than consulting, including serving as faculty or as a speaker at a vCash or cash equivalent2025
2025-11-13UCB, Inc.$7,000Compensation for services other than consulting, including serving as faculty or as a speaker at a vCash or cash equivalent2025
2025-11-13UCB, Inc.$4,500Compensation for services other than consulting, including serving as faculty or as a speaker at a vCash or cash equivalent2025
2025-11-13Incyte Corporation$1,193Travel and LodgingCash or cash equivalentOpzelura Drug, Dermatology2025
2025-11-13UCB, Inc.$80Travel and LodgingIn-kind items and services2025
2025-11-13Incyte Corporation$9Travel and LodgingCash or cash equivalentOpzelura Drug, Dermatology2025
2025-11-12GENZYME CORPORATION$5,551Compensation for services other than consulting, including serving as faculty or as a speaker at a vCash or cash equivalentDUPIXENT Biological, Immunology2025
2025-11-12Incyte Corporation$1,592Travel and LodgingCash or cash equivalentOpzelura Drug, Dermatology2025
2025-11-12Incyte Corporation$228Travel and LodgingCash or cash equivalentOpzelura Drug, Dermatology2025
2025-11-12Incyte Corporation$43Food and BeverageCash or cash equivalentOpzelura Drug, Dermatology2025
2025-11-11GENZYME CORPORATION$8,967Compensation for services other than consulting, including serving as faculty or as a speaker at a vCash or cash equivalentDUPIXENT Biological, Immunology2025
2025-11-11ABBVIE INC.$2,600Consulting FeeCash or cash equivalentSKYRIZI Biological, IMMUNOLOGY2025
2025-11-11GENZYME CORPORATION$2,010Travel and LodgingIn-kind items and servicesDUPIXENT Biological, Immunology2025
2025-11-11GENZYME CORPORATION$261Travel and LodgingIn-kind items and servicesDUPIXENT Biological, Immunology2025
2025-11-11GENZYME CORPORATION$107Food and BeverageIn-kind items and servicesDUPIXENT Biological, Immunology2025
2025-11-10ABBVIE INC.$650Consulting FeeCash or cash equivalentRINVOQ Biological, IMMUNOLOGY2025
2025-11-10ABBVIE INC.$27Food and BeverageIn-kind items and servicesRINVOQ Biological, IMMUNOLOGY2025
2025-11-06UCB, Inc.$7,000Compensation for services other than consulting, including serving as faculty or as a speaker at a vCash or cash equivalent2025
2025-11-06UCB, Inc.$53Travel and LodgingCash or cash equivalent2025
2025-11-06UCB, Inc.$33Food and BeverageCash or cash equivalent2025
2025-11-06UCB, Inc.$13Travel and LodgingCash or cash equivalent2025
2025-11-05Incyte Corporation$4,500Compensation for services other than consulting, including serving as faculty or as a speaker at a vCash or cash equivalentOpzelura Drug, Dermatology2025
2025-11-05Incyte Corporation$4,500Compensation for services other than consulting, including serving as faculty or as a speaker at a vCash or cash equivalentOpzelura Drug, Dermatology2025
2025-11-04UCB, Inc.$589Travel and LodgingIn-kind items and services2025
2025-11-04Arcutis Biotherapeutics, Inc.$11Food and BeverageIn-kind items and servicesZoryve Drug, Dermatology2025
2025-11-03Galderma Laboratories, L.P.$5,600Consulting FeeCash or cash equivalentNEMLUVIO Drug, DERMATITIS2025
2025-10-30Incyte Corporation$1,016Travel and LodgingCash or cash equivalentOpzelura Drug, Dermatology2025
2025-10-30Incyte Corporation$120Food and BeverageCash or cash equivalentOpzelura Drug, Dermatology2025
2025-10-30ABBVIE INC.$17Food and BeverageIn-kind items and servicesSKYRIZI Biological, IMMUNOLOGY2025
2025-10-29Incyte Corporation$4,500Compensation for services other than consulting, including serving as faculty or as a speaker at a vCash or cash equivalentOpzelura Drug, Dermatology2025
2025-10-29Incyte Corporation$2,250Compensation for services other than consulting, including serving as faculty or as a speaker at a vCash or cash equivalentOpzelura Drug, Dermatology2025
2025-10-29Incyte Corporation$889Travel and LodgingCash or cash equivalentOpzelura Drug, Dermatology2025
2025-10-28ABBVIE INC.$14Food and BeverageIn-kind items and servicesRINVOQ Biological, IMMUNOLOGY2025
2025-10-27Incyte Corporation$29Food and BeverageCash or cash equivalentOPZELURA Drug, Dermatology2025
2025-10-25Galderma Laboratories, L.P.$149Food and BeverageIn-kind items and servicesNEMLUVIO Drug, DERMATITIS2025
2025-10-25Galderma Laboratories, L.P.$99Food and BeverageIn-kind items and servicesNEMLUVIO Drug, DERMATITIS2025
2025-10-25LEO Pharma Inc.$35Food and BeverageIn-kind items and servicesANZUPGO Drug, DERMATOLOGY2025
2025-10-25Galderma Laboratories, L.P.$29Food and BeverageIn-kind items and servicesNEMLUVIO Drug, DERMATITIS2025
2025-10-25Janssen Biotech, Inc.$13Food and BeverageIn-kind items and servicesTREMFYA Drug, Immunology2025
2025-10-24Eli Lilly and Company$4,400Compensation for services other than consulting, including serving as faculty or as a speaker at a vCash or cash equivalentTALTZ Drug, Immunology2025
2025-10-24SANOFI US SERVICES INC.$2,335Consulting FeeCash or cash equivalentAYVAKIT Biological, Gastroenterology2025
2025-10-24Incyte Corporation$486Travel and LodgingCash or cash equivalentOpzelura Drug, Dermatology2025
2025-10-24Incyte Corporation$315Travel and LodgingCash or cash equivalentOpzelura Drug, Dermatology2025
2025-10-24Incyte Corporation$181Travel and LodgingCash or cash equivalentOpzelura Drug, Dermatology2025
2025-10-24ABBVIE INC.$92Food and BeverageIn-kind items and servicesRINVOQ Biological, IMMUNOLOGY2025
2025-10-24Incyte Corporation$43Travel and LodgingCash or cash equivalentOpzelura Drug, Dermatology2025
2025-10-24Incyte Corporation$26Food and BeverageCash or cash equivalentOpzelura Drug, Dermatology2025
2025-10-24Incyte Corporation$22Travel and LodgingCash or cash equivalentOpzelura Drug, Dermatology2025
2025-10-24Incyte Corporation$22Food and BeverageCash or cash equivalentOpzelura Drug, Dermatology2025
2025-10-24Incyte Corporation$18Travel and LodgingCash or cash equivalentOpzelura Drug, Dermatology2025
2025-10-24Incyte Corporation$18Food and BeverageCash or cash equivalentOpzelura Drug, Dermatology2025
2025-10-23Incyte Corporation$185Travel and LodgingCash or cash equivalentOpzelura Drug, Dermatology2025
2025-10-23UCB, Inc.$135Travel and LodgingIn-kind items and services2025
2025-10-23UCB, Inc.$135Travel and LodgingIn-kind items and services2025
2025-10-23UCB, Inc.$135Travel and LodgingIn-kind items and services2025
2025-10-23Incyte Corporation$57Travel and LodgingCash or cash equivalentOpzelura Drug, Dermatology2025
2025-10-23ABBVIE INC.$38Food and BeverageIn-kind items and servicesRINVOQ Biological, IMMUNOLOGY2025
2025-10-23LEO Pharma Inc.$30Food and BeverageIn-kind items and servicesSPEVIGO Biological, DERMATOLOGY2025
2025-10-23ABBVIE INC.$14Food and BeverageIn-kind items and servicesRINVOQ Biological, IMMUNOLOGY2025
2025-10-22UCB, Inc.$374Travel and LodgingIn-kind items and services2025
2025-10-22UCB, Inc.$154Food and BeverageIn-kind items and services2025
2025-10-22Incyte Corporation$112Food and BeverageCash or cash equivalentOpzelura Drug, Dermatology2025
2025-10-22UCB, Inc.$79Travel and LodgingIn-kind items and services2025
2025-10-22UCB, Inc.$79Travel and LodgingIn-kind items and services2025
2025-10-22UCB, Inc.$79Travel and LodgingIn-kind items and services2025
2025-10-22UCB, Inc.$70Travel and LodgingIn-kind items and services2025
2025-10-22UCB, Inc.$70Travel and LodgingIn-kind items and services2025
2025-10-22UCB, Inc.$70Travel and LodgingIn-kind items and services2025
2025-10-21UCB, Inc.$388Travel and LodgingIn-kind items and services2025
2025-10-21UCB, Inc.$388Travel and LodgingIn-kind items and services2025
2025-10-21UCB, Inc.$78Food and BeverageIn-kind items and services2025
2025-10-21UCB, Inc.$72Food and BeverageIn-kind items and services2025
2025-10-20UCB, Inc.$151Travel and LodgingIn-kind items and services2025
2025-10-20UCB, Inc.$151Travel and LodgingIn-kind items and services2025
2025-10-20UCB, Inc.$151Travel and LodgingIn-kind items and services2025
2025-10-20UCB, Inc.$113Travel and LodgingIn-kind items and services2025
2025-10-20UCB, Inc.$113Travel and LodgingIn-kind items and services2025
2025-10-20UCB, Inc.$113Travel and LodgingIn-kind items and services2025
2025-10-20Cipher Pharmaceuticals US LLC$18Food and BeverageCash or cash equivalentNatroba Drug, Antiparasitic2025
2025-10-18UCB, Inc.$59Food and BeverageIn-kind items and services2025
2025-10-18UCB, Inc.$10Travel and LodgingIn-kind items and services2025
2025-10-18UCB, Inc.$10Travel and LodgingIn-kind items and services2025
2025-10-18UCB, Inc.$10Travel and LodgingIn-kind items and services2025
2025-10-18UCB, Inc.$10Travel and LodgingIn-kind items and services2025
2025-10-18UCB, Inc.$10Travel and LodgingIn-kind items and services2025
2025-10-18UCB, Inc.$10Travel and LodgingIn-kind items and services2025
2025-10-16Incyte Corporation$4,500Compensation for services other than consulting, including serving as faculty or as a speaker at a vCash or cash equivalentOpzelura Drug, Dermatology2025
2025-10-16Incyte Corporation$4,500Compensation for services other than consulting, including serving as faculty or as a speaker at a vCash or cash equivalentOpzelura Drug, Dermatology2025
2025-10-16Incyte Corporation$2,250Compensation for services other than consulting, including serving as faculty or as a speaker at a vCash or cash equivalentOpzelura Drug, Dermatology2025
2025-10-16LEO Pharma Inc.$1,200Consulting FeeCash or cash equivalentANZUPGO Drug, DERMATOLOGY2025
2025-10-16Novartis Pharmaceuticals Corporation$22Food and BeverageIn-kind items and servicesCOSENTYX Drug, Dermatology2025
2025-10-16Novartis Pharmaceuticals Corporation$20Food and BeverageIn-kind items and servicesCOSENTYX Drug, Dermatology2025
2025-10-15UCB, Inc.$1,190Travel and LodgingIn-kind items and services2025
2025-10-15UCB, Inc.$566Travel and LodgingIn-kind items and services2025
2025-10-15UCB, Inc.$150Travel and LodgingIn-kind items and services2025
2025-10-15UCB, Inc.$84Food and BeverageIn-kind items and services2025
2025-10-14Incyte Corporation$28Food and BeverageCash or cash equivalentOPZELURA Drug, Dermatology2025
2025-10-11Janssen Biotech, Inc.$1,913Compensation for services other than consulting, including serving as faculty or as a speaker at a vCash or cash equivalentTREMFYA Drug, Immunology2025
2025-10-10PFIZER INC.$885Travel and LodgingIn-kind items and servicesCIBINQO Drug, Inflammation & Immunology2025
2025-10-09Incyte Corporation$750Compensation for services other than consulting, including serving as faculty or as a speaker at a vCash or cash equivalentOpzelura Drug, Dermatology2025
2025-10-08ABBVIE INC.$1,725Compensation for services other than consulting, including serving as faculty or as a speaker at a vCash or cash equivalentSKYRIZI Biological, IMMUNOLOGY2025
2025-10-08Incyte Corporation$953Travel and LodgingCash or cash equivalentOpzelura Drug, Dermatology2025
2025-10-08Incyte Corporation$131Food and BeverageCash or cash equivalentOpzelura Drug, Dermatology2025
2025-10-07PFIZER INC.$4,250Compensation for services other than consulting, including serving as faculty or as a speaker at a vCash or cash equivalentCIBINQO Drug, Inflammation & Immunology2025
2025-10-04PFIZER INC.$1,036Travel and LodgingIn-kind items and servicesLITFULO Drug, IMMUNOLOGY2025
2025-10-04Eli Lilly and Company$754Travel and LodgingIn-kind items and services2025
2025-10-04Eli Lilly and Company$197Travel and LodgingIn-kind items and services2025
2025-10-04Eli Lilly and Company$197Travel and LodgingIn-kind items and services2025
2025-10-04Eli Lilly and Company$115Travel and LodgingIn-kind items and services2025
2025-10-04Eli Lilly and Company$115Travel and LodgingIn-kind items and services2025
2025-10-04UCB, Inc.$15Travel and LodgingIn-kind items and services2025
2025-10-02UCB, Inc.$7,000Compensation for services other than consulting, including serving as faculty or as a speaker at a vCash or cash equivalent2025
2025-10-02Incyte Corporation$4,500Compensation for services other than consulting, including serving as faculty or as a speaker at a vCash or cash equivalentOpzelura Drug, Dermatology2025
2025-10-02Incyte Corporation$4,500Compensation for services other than consulting, including serving as faculty or as a speaker at a vCash or cash equivalentOpzelura Drug, Dermatology2025
2025-10-02Incyte Corporation$2,250Compensation for services other than consulting, including serving as faculty or as a speaker at a vCash or cash equivalentOpzelura Drug, Dermatology2025
2025-10-02Incyte Corporation$906Travel and LodgingCash or cash equivalentOpzelura Drug, Dermatology2025
2025-10-02Incyte Corporation$814Travel and LodgingCash or cash equivalentOpzelura Drug, Dermatology2025
2025-10-02Incyte Corporation$120Food and BeverageCash or cash equivalentOpzelura Drug, Dermatology2025
2025-10-02UCB, Inc.$70Travel and LodgingIn-kind items and services2025
2025-10-02UCB, Inc.$68Travel and LodgingCash or cash equivalent2025
2025-10-02UCB, Inc.$65Travel and LodgingCash or cash equivalent2025

The latest 200 records of 1,776.

Research payments naming this person as principal investigator

DateCompanyPaid toAmountStudyYear
2025-12-31ABBVIE INC.INTEGRATIVE SKIN SCIENCE AND RESEARCH$1,529A Phase 3 randomized, placebo-controlled, double-blind program to evaluate efficacy and safety of upadacitinib in adult 2025
2025-12-31ABBVIE INC.INTEGRATIVE SKIN SCIENCE AND RESEARCH$3,537A Phase 3, Randomized, Placebo-Controlled, Double-Blind Study to Evaluate the Efficacy, Safety, and Tolerability of Upad2025
2025-12-31PFIZER INC.INTEGRATIVE SKIN SCIENCE AND RESEARCH$7,771A PHASE 3 RANDOMIZED DOUBLEBLIND 52WEEK PLACEBOCONTROLLED MULTICENTER STUDY WITH A DOUBLEBLIND 52WEEK EXTENSION PERIOD W2025
2025-12-25Janssen Research & Development, LLCINTEGRATIVE SKIN SCIENCE AND RESEAR$2,291A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of JNJ-7722025
2025-12-25Janssen Research & Development, LLCINTEGRATIVE SKIN SCIENCE AND RESEAR$31,641A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled and Ustekinumab Active Comparator-controlled Study t2025
2025-12-24ABBVIE INC.INTEGRATIVE SKIN SCIENCE$5,149A Study to Learn How Safe and Effective Risankizumab is When Compared to Deucravacitinib to Treat Participants With Mode2025
2025-12-22Janssen Research & Development, LLCINTEGRATIVE SKIN SCIENCE AND RESEAR$3,782A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled and Ustekinumab Active Comparator-controlled Study t2025
2025-12-19Janssen Research & Development, LLCINTEGRATIVE SKIN SCIENCE AND RESEAR$8,792A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled and Deucravacitinib Active Comparator-controlled Stu2025
2025-12-17PFIZER INC.INTEGRATIVE SKIN SCIENCE AND RESEARCH$5,981A PHASE 3 RANDOMIZED DOUBLEBLIND 52WEEK PLACEBOCONTROLLED MULTICENTER STUDY WITH A DOUBLEBLIND 52WEEK EXTENSION PERIOD W2025
2025-12-11ABBVIE INC.INTEGRATIVE SKIN SCIENCE$1,151A Study to Assess Change in Disease Activity and Adverse Events of Oral Upadacitinib in Adult and Adolescent Participant2025
2025-12-09Boehringer Ingelheim Pharmaceuticals, Inc.INTEGRATIVE SKIN SCIENCE AND RESEARCH$4,700Lunsayil LTE: An extension trial assessing long-term spesolimab treatment in patients with Hidradenitis Suppurativa (HS)2025
2025-12-04ABBVIE INC.INTEGRATIVE SKIN SCIENCE AND RESERCH$1,678Study to Evaluate Adverse Events and Change in Disease Activity in Participants Between 6 and 17 Years With Moderate to 2025
2025-12-04ABBVIE INC.INTEGRATIVE SKIN SCIENCE$26,833A Study to Assess Change in Disease Activity and Adverse Events of Oral Upadacitinib in Adult and Adolescent Participant2025
2025-12-04ABBVIE INC.INTEGRATIVE SKIN SCIENCE$11,131A Study to Learn How Safe and Effective Risankizumab is When Compared to Deucravacitinib to Treat Participants With Mode2025
2025-12-04ABBVIE INC.INTEGRATIVE SKIN SCIENCE$36,808A Study to Assess Disease Activity and Safety of Lutikizumab in Adult and Adolescent Participants With Moderate to Sever2025
2025-12-04ABBVIE INC.INTEGRATIVE SKIN SCIENCE$8,391A Study to Evaluate the Effectiveness and Safety of Treatments, Either Alone or in Combination, for the Treatment of Mod2025
2025-12-04ABBVIE INC.INTEGRATIVE SKIN SCIENCE$14,792A Study to Evaluate the Safety and Effectiveness of Upadacitinib Tablets in Adult and Adolescent Participants With Sever2025
2025-12-04ABBVIE INC.INTEGRATIVE SKIN SCIENCE$15,057A Study of Upadacitinib in Adult Participants With Moderate-to-Severe Atopic Dermatitis and Inadequate Response to Dupil2025
2025-12-04ABBVIE INC.INTEGRATIVE SKIN SCIENCE$454A Study of Upadacitinib in Adult Participants With Moderate-to-Severe Atopic Dermatitis and Inadequate Response to Dupil2025
2025-12-04ABBVIE INC.INTEGRATIVE SKIN SCIENCE$18,974A Study To Assess Adverse Events and Effectiveness of Upadacitinib Oral Tablets in Adult and Adolescent Participants Wit2025
2025-12-03PFIZER INC.INTEGRATIVE SKIN SCIENCE AND RESEARCH$5,329A PHASE 3 RANDOMIZED DOUBLEBLIND 52WEEK PLACEBOCONTROLLED MULTICENTER STUDY WITH A DOUBLEBLIND 52WEEK EXTENSION PERIOD W2025
2025-11-26PFIZER INC.INTEGRATIVE SKIN SCIENCE AND RESEARCH$10,938A PHASE 3 RANDOMIZED DOUBLEBLIND 52WEEK PLACEBOCONTROLLED MULTICENTER STUDY WITH A DOUBLEBLIND 52WEEK EXTENSION PERIOD W2025
2025-11-25PFIZER INC.INTEGRATIVE SKIN SCIENCE AND RESEARCH$1,746A PHASE 3 RANDOMIZED DOUBLEBLIND 52WEEK PLACEBOCONTROLLED MULTICENTER STUDY WITH A DOUBLEBLIND 52WEEK EXTENSION PERIOD W2025
2025-11-20ABBVIE INC.INTEGRATIVE SKIN SCIENCE$11,307A Study to Assess Disease Activity and Safety of Lutikizumab in Adult and Adolescent Participants With Moderate to Sever2025
2025-11-20ABBVIE INC.INTEGRATIVE SKIN SCIENCE$2,299A Study of Upadacitinib in Adult Participants With Moderate-to-Severe Atopic Dermatitis and Inadequate Response to Dupil2025
2025-11-20ABBVIE INC.INTEGRATIVE SKIN SCIENCE$4,735A Study To Assess Adverse Events and Effectiveness of Upadacitinib Oral Tablets in Adult and Adolescent Participants Wit2025
2025-11-20ABBVIE INC.INTEGRATIVE SKIN SCIENCE AND RESERCH$515Study to Evaluate Adverse Events and Change in Disease Activity in Participants Between 6 and 17 Years With Moderate to 2025
2025-11-19ABBVIE INC.INTEGRATIVE SKIN SCIENCE$1,054A Study to Evaluate the Safety and Effectiveness of Upadacitinib Tablets in Adult and Adolescent Participants With Sever2025
2025-11-13ABBVIE INC.INTEGRATIVE SKIN SCIENCE$15,020A Study to Assess Disease Activity and Safety of Lutikizumab in Adult and Adolescent Participants With Moderate to Sever2025
2025-11-13ABBVIE INC.INTEGRATIVE SKIN SCIENCE$2,562A Study to Learn How Safe and Effective Risankizumab is When Compared to Deucravacitinib to Treat Participants With Mode2025
2025-11-05ABBVIE INC.INTEGRATIVE SKIN SCIENCE$44,453A Study to Assess Disease Activity and Safety of Lutikizumab in Adult and Adolescent Participants With Moderate to Sever2025
2025-11-05ABBVIE INC.INTEGRATIVE SKIN SCIENCE$5,007A Study to Learn How Safe and Effective Risankizumab is When Compared to Deucravacitinib to Treat Participants With Mode2025
2025-11-05ABBVIE INC.INTEGRATIVE SKIN SCIENCE$16,251A Study to Evaluate the Effectiveness and Safety of Treatments, Either Alone or in Combination, for the Treatment of Mod2025
2025-11-05ABBVIE INC.INTEGRATIVE SKIN SCIENCE$5,138A Study of Upadacitinib in Adult Participants With Moderate-to-Severe Atopic Dermatitis and Inadequate Response to Dupil2025
2025-11-05PFIZER INC.INTEGRATIVE SKIN SCIENCE AND RESEARCH$3,093A PHASE 3 RANDOMIZED DOUBLEBLIND 52WEEK PLACEBOCONTROLLED MULTICENTER STUDY WITH A DOUBLEBLIND 52WEEK EXTENSION PERIOD W2025
2025-11-04ABBVIE INC.INTEGRATIVE SKIN SCIENCE$37,237A Study To Assess Adverse Events and Effectiveness of Upadacitinib Oral Tablets in Adult and Adolescent Participants Wit2025
2025-11-04ABBVIE INC.INTEGRATIVE SKIN SCIENCE$12,630A Study to Assess Change in Disease Activity and Adverse Events of Oral Upadacitinib in Adult and Adolescent Participant2025
2025-11-04Eli Lilly and CompanyNORCAL MEDICAL RESEARCH INC$17,182A PHASE 4, MULTICENTER, OPEN-LABEL, SINGLE-ARM STUDY TO INVESTIGATE THE EFFICACY OF LEBRIKIZUMAB IN ADULT AND ADOLESCENT2025
2025-11-04ABBVIE INC.INTEGRATIVE SKIN SCIENCE$13,316A Study to Evaluate the Safety and Effectiveness of Upadacitinib Tablets in Adult and Adolescent Participants With Sever2025
2025-11-03Eli Lilly and CompanyINTEGRATIVE SKIN SCIENCE AND RESEARCH$6,560A PHASE 4, PROSPECTIVE, OPEN-LABEL, SINGLE ARM STUDY TO ASSESS THE EFFECTIVENESS OF TIRZEPATIDE AFTER INITIATION OF IXEK2025
2025-11-03Janssen Research & Development, LLCINTEGRATIVE SKIN SCIENCE AND RESEAR$1,710A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled and Deucravacitinib Active Comparator-controlled Stu2025
2025-10-31Janssen Research & Development, LLCINTEGRATIVE SKIN SCIENCE AND RESEAR$1,926A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of JNJ-7722025
2025-10-30E.R. Squibb & Sons, L.L.C.INTEGRATIVE SKIN SCIENCE AND RESEARCH$61A Phase 3b/4 Multi-center, Randomized, Open-label, Long-term Safety Study of Deucravacitinib in Comparison to Ustekinuma2025
2025-10-29PFIZER INC.INTEGRATIVE SKIN SCIENCE AND RESEARCH$1,746A PHASE 3 RANDOMIZED DOUBLEBLIND 52WEEK PLACEBOCONTROLLED MULTICENTER STUDY WITH A DOUBLEBLIND 52WEEK EXTENSION PERIOD W2025
2025-10-28Novartis Pharmaceuticals CorporationINTEGRATIVE SKIN SCIENCE AND RESEARCH$1,143A Multicenter, Randomized, Double-blind, Placebo-controlled, Phase II Platform Study to Assess the Efficacy and Safety o2025
2025-10-28Boehringer Ingelheim Pharmaceuticals, Inc.INTEGRATIVE SKIN SCIENCE AND RESEARCH$12,180Randomised, double-blind, placebo-controlled, Phase IIb/Phase III study to evaluate the efficacy and safety of spesolima2025
2025-10-27Eli Lilly and CompanyNORCAL MEDICAL RESEARCH INC$6,560A PHASE 4, PROSPECTIVE, OPEN-LABEL, SINGLE ARM STUDY TO ASSESS THE EFFECTIVENESS OF TIRZEPATIDE AFTER INITIATION OF IXEK2025
2025-10-24Janssen Research & Development, LLCINTEGRATIVE SKIN SCIENCE AND RESEAR$12,440A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled and Ustekinumab Active Comparator-controlled Study t2025
2025-10-22PFIZER INC.INTEGRATIVE SKIN SCIENCE AND RESEARCH$1,584A PHASE 3 RANDOMIZED DOUBLEBLIND 52WEEK PLACEBOCONTROLLED MULTICENTER STUDY WITH A DOUBLEBLIND 52WEEK EXTENSION PERIOD W2025
2025-10-20Janssen Research & Development, LLCINTEGRATIVE SKIN SCIENCE AND RESEAR$13,000A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled and Ustekinumab Active Comparator-controlled Study t2025
2025-10-20Janssen Research & Development, LLCINTEGRATIVE SKIN SCIENCE AND RESEAR$313A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of JNJ-7722025
2025-10-17ABBVIE INC.INTEGRATIVE SKIN SCIENCE$712A Study of Upadacitinib in Adult Participants With Moderate-to-Severe Atopic Dermatitis and Inadequate Response to Dupil2025
2025-10-15ABBVIE INC.INTEGRATIVE SKIN SCIENCE$4,587A Study to Assess Change in Disease Activity and Adverse Events of Oral Upadacitinib in Adult and Adolescent Participant2025
2025-10-15ABBVIE INC.INTEGRATIVE SKIN SCIENCE$1,132A Study to Evaluate the Safety and Effectiveness of Upadacitinib Tablets in Adult and Adolescent Participants With Sever2025
2025-10-15ABBVIE INC.INTEGRATIVE SKIN SCIENCE$2,469A Study to Assess Change in Disease Activity and Adverse Events of Oral Upadacitinib in Adult and Adolescent Participant2025
2025-10-15ABBVIE INC.INTEGRATIVE SKIN SCIENCE$6,455A Study To Assess Adverse Events and Effectiveness of Upadacitinib Oral Tablets in Adult and Adolescent Participants Wit2025
2025-10-09Eli Lilly and CompanyOSMAN DERMATOLOGY$3,000A LONG-TERM STUDY TO ASSESS THE SAFETY AND EFFICACY OF LEBRIKIZUMAB IN PATIENTS WITH MODERATE-TO-SEVERE ATOPIC DERMATITI2025
2025-10-09ABBVIE INC.INTEGRATIVE SKIN SCIENCE$50,244A Study to Assess Disease Activity and Safety of Lutikizumab in Adult and Adolescent Participants With Moderate to Sever2025
2025-10-09ABBVIE INC.INTEGRATIVE SKIN SCIENCE$4,372A Study to Evaluate the Safety and Effectiveness of Upadacitinib Tablets in Adult and Adolescent Participants With Sever2025
2025-10-09ABBVIE INC.INTEGRATIVE SKIN SCIENCE$29,267A Study to Assess Change in Disease Activity and Adverse Events of Oral Upadacitinib in Adult and Adolescent Participant2025
2025-10-09ABBVIE INC.INTEGRATIVE SKIN SCIENCE$2,091A Study of Upadacitinib in Adult Participants With Moderate-to-Severe Atopic Dermatitis and Inadequate Response to Dupil2025
2025-10-09ABBVIE INC.INTEGRATIVE SKIN SCIENCE$20,391A Study To Assess Adverse Events and Effectiveness of Upadacitinib Oral Tablets in Adult and Adolescent Participants Wit2025
2025-10-09ABBVIE INC.INTEGRATIVE SKIN SCIENCE$3,339A Study to Evaluate the Effectiveness and Safety of Treatments, Either Alone or in Combination, for the Treatment of Mod2025
2025-10-09ABBVIE INC.INTEGRATIVE SKIN SCIENCE$9,634A Study to Learn How Safe and Effective Risankizumab is When Compared to Deucravacitinib to Treat Participants With Mode2025
2025-10-09ABBVIE INC.INTEGRATIVE SKIN SCIENCE AND RESERCH$1,470Study to Evaluate Adverse Events and Change in Disease Activity in Participants Between 6 and 17 Years With Moderate to 2025
2025-10-08Boehringer Ingelheim Pharmaceuticals, Inc.INTEGRATIVE SKIN SCIENCE AND RESEARCH$68,502Randomised, double-blind, placebo-controlled, Phase IIb/Phase III study to evaluate the efficacy and safety of spesolima2025
2025-10-08Novartis Pharmaceuticals CorporationINTEGRATIVE SKIN SCIENCE AND RESEARCH$13,404A US Phase 3b, Multi-center, Randomized, Double-blind, Double-Dummy Study to Evaluate Efficacy of Remibrutinib Compared 2025
2025-10-07Boehringer Ingelheim Pharmaceuticals, Inc.Northwestern University$38,638Randomised, double-blind, placebo-controlled, Phase IIb/Phase III study to evaluate the efficacy and safety of spesolima2025
2025-10-04PFIZER INC.INTEGRATIVE SKIN SCIENCE AND RESEARCH$62A PHASE 3 RANDOMIZED DOUBLEBLIND 52WEEK PLACEBOCONTROLLED MULTICENTER STUDY WITH A DOUBLEBLIND 52WEEK EXTENSION PERIOD W2025
2025-10-01ABBVIE INC.INTEGRATIVE SKIN SCIENCE$13,248Skin Care2025
2025-09-29Janssen Research & Development, LLCINTEGRATIVE SKIN SCIENCE AND RESEAR CH$2,596A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of JNJ-7722025
2025-09-29Janssen Research & Development, LLCINTEGRATIVE SKIN SCIENCE AND RESEAR CH$15,414A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled and Ustekinumab Active Comparator-controlled Study t2025
2025-09-29Janssen Research & Development, LLCINTEGRATIVE SKIN SCIENCE AND RESEAR CH$6,840A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled and Deucravacitinib Active Comparator-controlled Stu2025
2025-09-26PFIZER INC.INTEGRATIVE SKIN SCIENCE AND RESEARCH$2,888A PHASE 3 RANDOMIZED DOUBLEBLIND 52WEEK PLACEBOCONTROLLED MULTICENTER STUDY WITH A DOUBLEBLIND 52WEEK EXTENSION PERIOD W2025
2025-09-23Boehringer Ingelheim Pharmaceuticals, Inc.INTEGRATIVE SKIN SCIENCE AND RESEARCH$18,201Lunsayil LTE: An extension trial assessing long-term spesolimab treatment in patients with Hidradenitis Suppurativa (HS)2025
2025-09-22Janssen Research & Development, LLCINTEGRATIVE SKIN SCIENCE AND RESEAR CH$698A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled and Deucravacitinib Active Comparator-controlled Stu2025
2025-09-19PFIZER INC.INTEGRATIVE SKIN SCIENCE AND RESEARCH$6,218A PHASE 3 RANDOMIZED DOUBLEBLIND 52WEEK PLACEBOCONTROLLED MULTICENTER STUDY WITH A DOUBLEBLIND 52WEEK EXTENSION PERIOD W2025
2025-09-12PFIZER INC.INTEGRATIVE SKIN SCIENCE AND RESEARCH$53,231A PHASE 3 RANDOMIZED DOUBLEBLIND 52WEEK PLACEBOCONTROLLED MULTICENTER STUDY WITH A DOUBLEBLIND 52WEEK EXTENSION PERIOD W2025
2025-09-11ABBVIE INC.INTEGRATIVE SKIN SCIENCE$17,610A Study to Assess Disease Activity and Safety of Lutikizumab in Adult and Adolescent Participants With Moderate to Sever2025
2025-09-11ABBVIE INC.INTEGRATIVE SKIN SCIENCE$3,160A Study to Evaluate the Safety and Effectiveness of Upadacitinib Tablets in Adult and Adolescent Participants With Sever2025
2025-09-11ABBVIE INC.INTEGRATIVE SKIN SCIENCE$8,656A Study to Learn How Safe and Effective Risankizumab is When Compared to Deucravacitinib to Treat Participants With Mode2025
2025-09-11ABBVIE INC.INTEGRATIVE SKIN SCIENCE$1,404A Study of Upadacitinib in Adult Participants With Moderate-to-Severe Atopic Dermatitis and Inadequate Response to Dupil2025
2025-09-11ABBVIE INC.INTEGRATIVE SKIN SCIENCE$3,952A Study To Assess Adverse Events and Effectiveness of Upadacitinib Oral Tablets in Adult and Adolescent Participants Wit2025
2025-09-11ABBVIE INC.INTEGRATIVE SKIN SCIENCE AND RESERCH$515Study to Evaluate Adverse Events and Change in Disease Activity in Participants Between 6 and 17 Years With Moderate to 2025
2025-09-08Janssen Research & Development, LLCINTEGRATIVE SKIN SCIENCE AND RESEAR CH$18,535A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled and Ustekinumab Active Comparator-controlled Study t2025
2025-09-04ABBVIE INC.INTEGRATIVE SKIN SCIENCE$29,426A Study to Learn How Safe and Effective Risankizumab is When Compared to Deucravacitinib to Treat Participants With Mode2025
2025-09-04ABBVIE INC.INTEGRATIVE SKIN SCIENCE$3,208A Study of Upadacitinib in Adult Participants With Moderate-to-Severe Atopic Dermatitis and Inadequate Response to Dupil2025
2025-09-04ABBVIE INC.INTEGRATIVE SKIN SCIENCE$45,354A Study to Assess Disease Activity and Safety of Lutikizumab in Adult and Adolescent Participants With Moderate to Sever2025
2025-09-04ABBVIE INC.INTEGRATIVE SKIN SCIENCE$4,330A Study of Upadacitinib in Adult Participants With Moderate-to-Severe Atopic Dermatitis and Inadequate Response to Dupil2025
2025-09-03ABBVIE INC.INTEGRATIVE SKIN SCIENCE$26,408A Study to Assess Change in Disease Activity and Adverse Events of Oral Upadacitinib in Adult and Adolescent Participant2025
2025-09-03ABBVIE INC.INTEGRATIVE SKIN SCIENCE AND RESERCH$1,470Study to Evaluate Adverse Events and Change in Disease Activity in Participants Between 6 and 17 Years With Moderate to 2025
2025-09-03ABBVIE INC.INTEGRATIVE SKIN SCIENCE$17,236A Study To Assess Adverse Events and Effectiveness of Upadacitinib Oral Tablets in Adult and Adolescent Participants Wit2025
2025-09-03ABBVIE INC.INTEGRATIVE SKIN SCIENCE$25,029A Study to Evaluate the Safety and Effectiveness of Upadacitinib Tablets in Adult and Adolescent Participants With Sever2025
2025-08-29ABBVIE INC.INTEGRATIVE SKIN SCIENCE$7,559A Study to Evaluate the Safety and Effectiveness of Upadacitinib Tablets in Adult and Adolescent Participants With Sever2025
2025-08-25Boehringer Ingelheim Pharmaceuticals, Inc.INTEGRATIVE SKIN SCIENCE AND RESEARCH$1,195Lunsayil LTE: An extension trial assessing long-term spesolimab treatment in patients with Hidradenitis Suppurativa (HS)2025
2025-08-25Janssen Research & Development, LLCINTEGRATIVE SKIN SCIENCE AND RESEAR CH$2,557A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled and Deucravacitinib Active Comparator-controlled Stu2025
2025-08-23PFIZER INC.INTEGRATIVE SKIN SCIENCE AND RESEARCH$7,552A PHASE 3 RANDOMIZED DOUBLEBLIND 52WEEK PLACEBOCONTROLLED MULTICENTER STUDY WITH A DOUBLEBLIND 52WEEK EXTENSION PERIOD W2025
2025-08-19ABBVIE INC.INTEGRATIVE SKIN SCIENCE$1,537A Study to Learn How Safe and Effective Risankizumab is When Compared to Deucravacitinib to Treat Participants With Mode2025
2025-08-13LEO Pharma ASINTEGRATIVE SKIN SCIENCE AND RESEARCH$1,000TRACE STUDY: TRALOKINUMAB REAL WORLD CLINICAL USE: AN OBSERVATIONAL COHORT STUDY OF ATOPIC DERMATITIS PATIENTS PRESCRIBE2025
2025-08-07ABBVIE INC.INTEGRATIVE SKIN SCIENCE$2,122A Study to Assess Change in Disease Activity and Adverse Events of Oral Upadacitinib in Adult and Adolescent Participant2025

CMS Open Payments: payments and transfers of value that drug and medical device makers and group purchasing organizations report to Medicare, program years 2019 on, as published by CMS (general, research and ownership records; refreshed by CMS each June and January). Links to other records on this site are by name (and state) only.

The area Census

Placer CountyRocklin city

County outline, the place (blue), the tract (orange) and the ZIP center (dot).

In Rocklin, CA, county Placer County, CA, state California; placed by its city name.

MeasurePlace (city or town)
Rocklin, CA
County
Placer County, CA
State
California
Population B0100373,327419,15639,287,377
Population, 2020 census P171,601404,73939,538,223
Median age B0100238.442.537.9
Under 18 B0100124.6%21.8%22.0%
65 and over B0100114.3%20.5%15.7%
Households B1100125,951157,95413,548,091
Foreign born B0500214.3%12.7%27.0%
Median household income B19013$124,168$115,998$99,122
Median family income B19113$153,926$138,699$113,346
Per capita income B19301$58,054$57,862$49,513
Poverty rate B170015.6%6.8%12.0%
Unemployment rate B230254.5%4.8%6.6%
Civilian labor force B2302536,623206,22820,068,466
Mean commute (minutes) B0801326.127.428.7
Bachelor's degree or higher B1500348.0%43.2%37.1%
Housing units B2500126,993179,26614,644,735
Owner-occupied B2500368.3%74.8%55.9%
Renters B2500331.7%25.2%44.1%
Median home value B25077$703,400$688,100$734,700
Median gross rent B25064$2,258$2,069$2,036
White, not Hispanic B0300261.5%65.5%33.8%
Black B030021.5%1.6%5.2%
Hispanic or Latino B0300216.0%15.7%40.2%
Asian B0300211.3%9.1%15.3%
American Indian and Alaska Native B030020.2%0.2%0.3%

Economy now FRED unemployment 5.1% in Sep 2026 (5.5% a year earlier); per capita personal income $90,957 in 2025, up 30% in five years (+4.3% after inflation); Unemployment rate: 5.5% in Sep 2016 to 5.1% in Sep 2026; low 3.8%, high 16.1% the state; Source: FRED, Federal Reserve Bank of St. Louis.

Data: IPUMS NHGIS (ACS 2020-2024 and the 2020 census); each figure links to its table for that area at data.census.gov. Records are placed by ZIP code and city name, not street address. More: everything FURP has in Rocklin, CA.

Comments

Anonymous: no account or email. Up to 2,000 characters, at most one link. Comments are checked automatically; some wait for review.